Intervacc (DB:2E9) - Stock Price, News & Analysis

2E9 Stock Overview

Develops novel veterinary vaccines for animals in Sweden. More details

2E9 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 104.86% per year

Risk Analysis

Makes less than USD$1m in revenue (SEK9M)

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Intervacc AB (publ) Competitors

Medigene

XTRA:MDG1

€22.5m

co.don

XTRA:CNW

€6.5m

Heidelberg Pharma

XTRA:HPHA

€102.1m

2invest

XTRA:2INV

€62.7m

Price History & Performance

Summary of all time highs, changes and price drops for Intervacc
Historical stock prices
Current Share Price	SEK 0.18
52 Week High	SEK 0.86
52 Week Low	SEK 0.13
Beta	0.62
11 Month Change	-24.30%
3 Month Change	-42.20%
1 Year Change	-66.98%
33 Year Change	-97.13%
5 Year Change	-90.61%
Change since IPO	-65.49%

Recent updates

Shareholder Returns

	2E9	DE Biotechs	DE Market
7D	9.5%	-0.2%	0.8%
1Y	-67.0%	-16.9%	9.1%

Return vs Industry: 2E9 underperformed the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: 2E9 underperformed the German Market which returned 8.5% over the past year.

Price Volatility

Is 2E9's price volatile compared to industry and market?
2E9 volatility
2E9 Average Weekly Movement	20.4%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 2E9's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 2E9's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1983	15	Jonas Sohlman	www.intervacc.se

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows.

Intervacc AB (publ) Fundamentals Summary

How do Intervacc's earnings and revenue compare to its market cap?
2E9 fundamental statistics
Market cap	€17.46m
Earnings (TTM)	-€6.70m
Revenue (TTM)	€804.79k

21.7x

P/S Ratio

-2.6x

P/E Ratio

Is 2E9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2E9 income statement (TTM)
Revenue	SEK 9.29m
Cost of Revenue	SEK 13.28m
Gross Profit	-SEK 3.99m
Other Expenses	SEK 73.34m
Earnings	-SEK 77.34m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)	-1.02
Gross Margin	-43.01%
Net Profit Margin	-832.82%
Debt/Equity Ratio	0.06%

How did 2E9 perform over the long term?

See historical performance and comparison

2E9 Stock Overview

Rewards

Risk Analysis

Intervacc AB (publ) Competitors

XTRA:MDG1

€22.5m

XTRA:CNW

€6.5m

XTRA:HPHA

€102.1m

XTRA:2INV

€62.7m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Recent updates

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings released: kr1.69 loss per share (vs kr1.28 loss in FY 2022)

Intervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)

Intervacc AB (publ) Announces Composition of Nomination Committee

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)

Intervacc AB (publ) Announces Executive Changes

Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova

New major risk - Shareholder dilution

Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.

Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member

The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months

Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Intervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023

Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)

Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the Uk

Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022

Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in Denmark

First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.13 loss in 1Q 2021)

Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against Mastitis

Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in Pigs

Full year 2021 earnings released: kr0.59 loss per share (vs kr0.55 loss in FY 2020)

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Intervacc AB (publ), Annual General Meeting, Jun 14, 2022

Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S

Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European Markets

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)

Forecast to breakeven in 2022

Forecast to breakeven in 2023

Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)

Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UK

Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EU

Independent Director Newton Aguiar has left the company

Forecast breakeven pushed back to 2023

First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)

Independent Director recently sold €2.9m worth of stock

New 90-day high: €7.54

Full year 2020 earnings released: kr0.54 loss per share (vs kr0.71 loss in FY 2019)

Intervacc AB (publ) to Report Q2, 2021 Results on Sep 03, 2021

Intervacc AB (publ), Annual General Meeting, Jun 09, 2021

New 90-day high: €5.55

Intervacc AB (Publ) Appoints Emma Hartman as Global Product Manager for Strangvac